GlassScriptPhysician profile
Bahar Madani
NPI 1730356106
$6,417.67
in general payments reported to CMS, 2019-2025
38 companies · $934 in 2025
The $934 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $428 · 2021: $726 · 2022: $1,320 · 2023: $873 · 2024: $941 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.93 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,855.12 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $772.18 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $755.17 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $566.91 | 2020-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $370.35 | 2019-2020 | |
| Genzyme Corporation | $221.60 | 2022-2025 | |
| Eisai INC. | $213.15 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $200.30 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $153.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $124.99 | 2020 | |
| Intercept Pharmaceuticals, INC. | $123.34 | 2019-2022 | |
| Ardelyx, INC. | $102.96 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $84.23 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $80.39 | 2019-2022 | |
| Lilly USA, LLC | $78.47 | 2024 | Omvoh |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahar Madani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.